Iscar for Supplemental Care in Stage IV Lung Cancer

• Sponsor: National Center for Complementary and Integrative Health (NCCIH) (NIH)
• Overall Status: Completed
• CT.gov ID: NCT00079794
• Collaborator: (none)
• Enrollment: 36
• Location: 1
• Duration (Months): 29
• Patients Per Site Per Month: 1.2

Study Details

Study Description

Brief Summary

The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.

Condition or Disease	Intervention/Treatment	Phase
Lung Cancer	Drug: Iscar; Drug: mistletoe	Phase 2

Detailed Description

See Brief Summary

Study Design

• Study Type: Interventional
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Iscar for Supplemental Care in Stage IV Lung Cancer
• Study Start Date: Sep 1, 2001
• Actual Primary Completion Date: Feb 1, 2004
• Actual Study Completion Date: Feb 1, 2004

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Stage IV NSCLC patients who receive standard chemotherapy

Exclusion criteria:

• Known allergy to Viscum Album L.

• Concomitant use of other mistletoe products

• Concomitant use of mushroom glucan and proteoglycan extracts

• Concomitant use of thymus extract products

• Inability to self-report quality of life utilizing assessment tools

• Ongoing steroid or ACTH therapy

• Co-morbid immunocompromised state

• Pregnancy

• Participation in other clinical trials

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Thomas Jefferson University	Philadelphia	Pennsylvania	United States	19107

Sponsors and Collaborators

• National Center for Complementary and Integrative Health (NCCIH)

Investigators

• Principal Investigator: Steven Rosenzweig, MD, Jefferson Medical College of Thomas Jefferson University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00079794
• Other Study ID Numbers: R21AT001020-01; Rosenzweig
• First Posted: Mar 16, 2004
• Last Update Posted: Jan 25, 2008
• Last Verified: Jan 1, 2008

• Keywords provided by , ,: lung cancer; herbal medicine; non-small cell cancer; Iscar; mistletoe
• Additional relevant MeSH terms: Lung Neoplasms

Study Results

No Results Posted as of Jan 25, 2008